Difference between revisions 6001770 and 6001771 on simplewiki

{{chembox
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 457631192
| ImageFileL1 = Ferrocene.svg
| ImageSizeL1 = 80 px
| ImageFileR1 = Ferrocene-from-xtal-3D-balls.png
| ImageSizeR1 = 80 px
(contracted; show full)

===Pharmaceutical===
Ferrocene derivatives have been investigated as drugs.<ref>{{cite journal|first1=Dave R. |last1=Van Staveren |first2=Nils |last2=Metzler-Nolte |title=Bioorganometallic Chemistry of Ferrocene |journal=[[Chemical Reviews|Chem. Rev.]]|date= 2004 |volume=104 |pages=5931–5986
|DOI=10.1021/cr0101510}}</ref> 
The anticancer activity of ferrocene derivatives was first studied in the late 1970s, when derivatives bearing [[amine]] or [[amide]] groups were tested against lymphocytic [[leukemia]].<ref name=":0">{{Cite journal|last=Ornelas|first=Catia|title=Application of ferrocene and its derivatives in cancer research|journal=New Journal of Chemistry|volume=35|doi=10.1039/c1nj20172g}}</ref> Some ferrocenium salts exhibit anticancer or [[antimalarial]] activity,<ref name="BiotNosten2011">{{cite journal|last1=Biot|first1=C.|last2=Nosten|first2=F.|last3=Fraisse|first3=L.|last4=Ter-Minassian|first4=D.|last5=Khalife|first5=J.|last6=Dive|first6=D.|title=The antimalarial ferroquine: from bench to clinic|journal=Parasite|volume=18|issue=3|year=2011|pages=207–214|issn=1252-607X|doi=10.1051/parasite/2011183207|url=http://www.parasite-journal.org/articles/parasite/full_html/2011/03/parasite2011183p207/parasite2011183p207.html|PMID=21894260|PMC=3671469}} {{open access}}</ref> and an experimental drug has been reported which is a ferrocenyl version of [[tamoxifen]].<ref name = top2003 />  The idea is that the tamoxifen will bind to the [[estrogen]] binding sites, resulting in a cytotoxicity effect.<ref name=top2003>{{cite journal|first1=S. |last1=Top |first2=A. |last2=Vessières |first3=G. |last3=Leclercq |first4=J. |last4=Quivy |first5=J. |last5=Tang |first6=J. |last6=Vaissermann|first7= M. |last7=Huché |first8=G. |last8=Jaouen| title=Synthesis, Biochemical Properties and Molecular Modelling Studies of Organometallic Specific Estrogen Receptor Modulators (SERMs), the Ferrocifens and Hydroxyferrocifens: Evidence for an Antiproliferative Effect of Hydroxyferrocifens on both Hormone-Dependent and Hormone-Independent Breast Cancer Cell Lines| journal=[[Chem. Eur. J.]]| year=2003| volume=9| pages=5223–36|pmid=14613131|doi=10.1002/chem.200305024|issue=21}}</ref><ref>{{cite journal|journal=[[Chemical and Engineering News]]|date=16 September 2002| title= The Bio Side of Organometallics|author= Ron Dagani| volume = 80| issue= 37| pages = 23–29| url=http://pubs.acs.org/cen/science/8037/8037sci1.html|doi=10.1021/cen-v080n037.p023}}</ref><ref>{{cite journal |first1=S. |last1=Top|first2= B. |last2=Dauer|first3= J.|last3= Vaissermann |first4=G.|last4= Jaouen| journal=[[Journal of Organometallic Chemistry|J. Organomet. Chem.]]| title= Facile route to ferrocifen, 1-[4-(2-dimethylaminoethoxy)]-1-(phenyl-2-ferrocenyl-but-1-ene), first organometallic analogue of tamoxifen, by the McMurry reaction|doi=10.1016/S0022-328X(97)00086-7 |year=1997| volume=541| pages= 355–361}}</ref> One mechanism proposed as to why the ferrocenyl version is more cytotoxic than tamoxifen is the formation of [[quinone methide]], which results from in situ oxidation of the ferrocene moiety.<ref>{{Cite journal|last=Heilmann|first=Julia B.|last2=Hillard|first2=Elizabeth A.|last3=Plamont|first3=Marie-Aude|last4=Pigeon|first4=Pascal|last5=Bolte|first5=Michael|last6=Jaouen|first6=Gérard|last7=Vessières|first7=Anne|title=Ferrocenyl compounds possessing protected phenol and thiophenol groups: Synthesis, X-ray structure, and in vitro biological effects against breast cancer|url=http://dx.doi.org.proxy.library.nd.edu/10.1016/j.jorganchem.2007.12.011|journal=Journal of Organometallic Chemistry|volume=693|issue=8-9|pages=1716–1722|doi=10.1016/j.jorganchem.2007.12.011}}</ref>  When the anticancer activity of the ferrocene version of tamoxifen is compared to compounds in which the ferrocene moiety is replaced by titanium, rhenium, and ruthenium, the ferrocene version shows the best anticancer activity.<ref name=":0" /><ref>{{Cite journal|last=Jaouen|first=Gérard|last2=Top|first2=Siden|last3=Vessières|first3=Anne|last4=Pigeon|first4=Pascal|last5=Leclercq|first5=Guy|last6=Laios|first6=Ionna|date=2001-01-01|title=First anti-oestrogen in the cyclopentadienyl rhenium tricarbonyl series. Synthesis and study of antiproliferative effects|url=http://xlink.rsc.org/?DOI=b009553m|journal=Chemical Communications|language=en|issue=4|pages=383–384|doi=10.1039/b009553m|issn=1364-548X}}</ref><ref>{{Cite journal|last=Top|first=Siden|last2=Vessières|first2=Anne|last3=Pigeon|first3=Pascal|last4=Rager|first4=Marie-Noëlle|last5=Huché|first5=Michel|last6=Salomon|first6=Emmanuel|last7=Cabestaing|first7=Claude|last8=Vaissermann|first8=Jacqueline|last9=Jaouen|first9=Gérard|date=2004-08-06|title=Selective Estrogen-Receptor Modulators (SERMs) in the Cyclopentadienylrhenium Tricarbonyl Series: Synthesis and Biological Behaviour|url=http://onlinelibrary.wiley.com/doi/10.1002/cbic.200400067/abstract|journal=ChemBioChem|language=en|volume=5|issue=8|pages=1104–1113|doi=10.1002/cbic.200400067|issn=1439-7633}}</ref>Only one drug has entered the clinic, ferrocenerone, used to treat some cases of iron-deficiency.<ref name=Babin/>

The anticancer activity of ferrocene derivatives was first investigted in the late 1970s, when derivatives bearing [[amine]] or [[amide]] groups were tested against lymphocytic [[leukemia]].<ref name=":0">{{Cite journal|last=Ornelas|first=Catia|title=Application of ferrocene and its derivatives in cancer research|journal=New Journal of Chemistry|volume=35|doi=10.1039/c1nj20172g}}</ref> Some ferrocenium salts exhibit anticancer activity, but no compound has seen evaluation in the clinic.<ref name=Babin>Babin, V. N., et al., "Ferrocenes as potential anticancer drugs. Facts and hypotheses", Russ. Chem. Bull. 2014, volume 63, 2405-2422. {{DOI|10.1007/s11172-014-0756-7}}</ref>  Particular success has been seen for [[antimalarial]] activity,<ref name="BiotNosten2011">{{cite journal|last1=Biot|first1=C.|last2=Nosten|first2=F.|last3=Fraisse|first3=L.|last4=Ter-Minassian|first4=D.|last5=Khalife|first5=J.|last6=Dive|first6=D.|title=The antimalarial ferroquine: from bench to clinic|journal=Parasite|volume=18|issue=3|year=2011|pages=207–214|issn=1252-607X|doi=10.1051/parasite/2011183207|url=http://www.parasite-journal.org/articles/parasite/full_html/2011/03/parasite2011183p207/parasite2011183p207.html|PMID=21894260|PMC=3671469}} {{open access}}</ref><ref>Roux, C.; Biot, C., "Ferrocene-based antimalarials", Future Med. Chem. 2012, 4, 783-797. {{DOI|10.4155/fmc.12.26}}</ref> 

===Materials chemistry===
Ferrocene, being readily decomposed to iron nanoparticles, can be used as a catalyst for the production of carbon nanotubes.<ref>{{cite journal|first1=Devin |last1=Conroya |first2=Anna |last2=Moisalab|first3= Silvana |last3=Cardosoa |first4=Alan |last4=Windleb |first5=John |last5=Davidson|journal=[[Chemical Engineering Science|Chem. Eng. Sci.]]|year=2010|volume=65|pages=2965–2977|doi=10.1016/j.ces.2010.01.019|title=Carbon nanotube reactor: Ferrocene decomposition, iron part(contracted; show full)
{{Authority control}}

[[Category:Organoiron compounds]]
[[Category:Metallocenes]]
[[Category:Antiknock agents]]
[[Category:Sandwich compounds]]
[[Category:Cyclopentadienyl complexes]]